A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping

Author(s)

Hook E1, Vioix H2, Batteson R1, McLean T3, Hatswell A1
1Delta Hat Ltd, Nottingham, UK, 2Merck Healthcare KGaA, Darmstadt, HE, Germany, 3Merck Serono Ltd, Feltham, UK

OBJECTIVES:

Health-related quality of life (HRQoL) data are routinely used to generate utilities for health technology assessment, with a range of methods available to calculate health state utility values (HSUVs). Values may depend on the questionnaire, value set, and statistical analysis performed. The Phase II VISION study (NCT02864992) of tepotinib in patients with NSCLC harboring METex14 skipping captured both EQ-5D-5L and EORTC QLQ-C30 responses. This study compares alternative HSUVs generated from VISION.

METHODS: EQ-5D utilities were derived from the UK EQ-5D crosswalk value set, and EORTC QLU-C10D utilities were derived from EORTC CLQ-C30 responses using the UK value set. To account for repeated measures, linear mixed models were fitted. Utilities were based on progression status (defined by investigator [INV] or independent evidence review committee [IRC]) and time to death (TTD). The correlation between paired observations of EQ-5D-5L and EORTC QLE-C10D was assessed using Pearson’s product moment correlation coefficient (PMCC).

RESULTS: From 273 patients with METex14 skipping NSCLC at the February 2021 data cut-off, 1,545 EQ-5D-5L and 1,546 EORTC QLQ-C30 responses were available. In general, EQ-5D produced higher estimated HSUVs than EORTC QLU-C10D. The difference between estimates was <0.02 (two decimal places) for all health states across models. Progression-based utilities were similar across progression definitions (INV, IRC), with differences only appearing at the third decimal place. EORTC QLU-C10D estimated greater utility in TTD categories closest to death (–0.0052 vs –0.0178). When comparing paired values, a statistically significant (p<0.001) correlation was found between EQ-5D and EORTC QLU-C10D HSUVs (PMCC: 0.693; 95% CI: 0.667, 0.718).

CONCLUSIONS:

A range of methods are available to generate HSUVs from HRQoL data. This analysis found high correlation between the well-established EQ-5D and novel QLU-C10D measures. Further research is required to understand when it is appropriate to use each method and the resulting impact on economic modeling.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

PCR153

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities

Disease

STA: Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×